Workflow
ADMA Biologics(ADMA)
icon
Search documents
ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue?
ZACKS· 2024-09-10 14:16
Have you been paying attention to shares of Adma Biologics (ADMA) ? Shares have been on the move with the stock up 11.7% over the past month. The stock hit a new 52-week high of $19.34 in the previous session. Adma Biologics has gained 306.6% since the start of the year compared to the 10.3% move for the Zacks Medical sector and the 0% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't mi ...
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
GlobeNewswire News Room· 2024-09-10 11:00
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference in New York, NY on September 17, 2024, at 3:05 p.m. ET. A live audio webcast of the call will be av ...
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
ZACKS· 2024-08-29 14:40
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Adma Biologics (ADMA) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Adma Biologics is a member of our Medical group, which includes 1017 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the ind ...
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
ZACKS· 2024-08-19 16:41
ADMA Biologics, Inc.’s (ADMA) shares have surged 31.4% in a month compared with the industry’s growth of 1.4%. The stock hit its 52-week high of $17.87 on Aug 14.The significant growth can be attributed to the company’s better-than-expected second-quarter results, wherein both the top and bottom-lines beat their estimates. The company also raised its annual guidance for 2024 and 2025 revenues and net income, based on the continuous growth of its unique and proprietary immunoglobulin, Asceniv.ADMA expects to ...
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
ZACKS· 2024-08-13 14:31
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently has an average brokerage recomme ...
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
ZACKS· 2024-08-13 14:16
Have you been paying attention to shares of Adma Biologics (ADMA) ? Shares have been on the move with the stock up 22.9% over the past month. The stock hit a new 52-week high of $17.04 in the previous session. Adma Biologics has gained 263.9% since the start of the year compared to the 6.7% move for the Zacks Medical sector and the -2.3% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it h ...
Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates
ZACKS· 2024-08-08 23:11
Adma Biologics (ADMA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.50%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.05 per share when it actually produced earnings of $0.08, delivering a surprise of 60%.Over the last four quar ...
ADMA Biologics(ADMA) - 2024 Q2 - Quarterly Report
2024-08-08 21:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or ...
ADMA Biologics(ADMA) - 2024 Q2 - Quarterly Results
2024-08-08 20:10
Exhibit 99.1 ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update 2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y 2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y 2Q 2024 Adjusted EBITDA(1) of $44.5 Million, a Nearly 600% Increase Y-o-Y Commercial Scale Production of ADMA's Innovative Biologics Manufacturing Process Supports a Potential Yield Enhancement of Approximately 20% from Same Starting Plasma FY 2024 and 2025 Total Revenue ...
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire News Room· 2024-08-01 11:00
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2024 financial results on August 8, 2024, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its fin ...